Status:
WITHDRAWN
Angiotensin 2 for Hepatorenal Syndrome
Lead Sponsor:
University of California, Los Angeles
Conditions:
Hepatorenal Syndrome
Cirrhosis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Hepatorenal syndrome (HRS) is a disease in which patients with cirrhosis (end stage liver failure) develop secondary kidney injury and failure. The current treatment available in the United States is ...
Eligibility Criteria
Inclusion
- Patients in the ICU with HRS-AKI defined as
- Acute kidney injury defined as an increase in serum creatinine (sCr) \>=0.3 mg/dl or \>=50% from baseline within 7 days
- Presence of cirrhosis and ascites
- Absence of other causes such as shock, nephrotoxic drugs, or other suspected causes of kidney injury.
- Lack of response to diuretic withdrawal and albumin challenge of 1 g/kg of body weight
Exclusion
- Age \<18 years
- Current or anticipated (within 24 hours) need for renal replacement therapy (RRT)
- Cr \> 6 mg/dl
- Renal transplantation status
- Fractional Excretion of Sodium (FeNa) \> 2%
- Pregnancy
- Recent Cerebrovascular Accident (CVA), Myocardial Infarction (MI), venous or arterial thrombosis (within last 3 months)
- Known hypercoagulable state other than cirrhosis
- Uncontrolled hypertension (SBP \> 160)
- Anticipated mortality within 72 hours
- Inability to obtain consent.
Key Trial Info
Start Date :
July 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2023
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04048707
Start Date
July 1 2021
End Date
July 1 2023
Last Update
March 6 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.